Maze Therapeutics, Inc.

NASDAQ:MAZE

Biotechnology

Healthcare
$31.20 +0.74%

+$0.18 today

Market cap
$1.71B
Beta
2.26
P/E (TTM)
-11.0
EPS (TTM)
-$2.27
52W Low $9.83High $53.65

Volume 0.71M

Average 0.84M

MAZE Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Maze Therapeutics, Inc.NASDAQ: MAZE

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows in line with its trailing trend

Q1 FY2026 operating expenses of $46.11M rose 30.2% year over year, in line with the +30.0% change in trailing-twelve-month operating expenses. Sequentially, it rose 22.8% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.

Context

  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +30.2% holds above the trailing-twelve-month pace of +30.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$46.11M+22.8% QoQ
Last fiscal yearDec 2025
$140.5M+27.8% YoY
LTMMar 2026
$152.46M+30.0% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+30.2%——
1 year+27.8%——
3-year CAGR+8.2%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
140.5M USD
Year-over-year change
+27.8%
3-year CAGR
+8.2%

Operating Expenses vs competitors

How MAZE compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +30.0% is the 4th highest of 8, against a peer median of +28.7%.
  • Operating expenses amounts to 762.3% of revenue for MAZE, versus a peer median of 145.7%.
MAZE Competitors
Operating Expenses for MAZE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TVTXTravere Therapeutics, Inc.LTM Sep 2026$753.04M USD+45.8%+8.5%115.7%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$712.31M USD-28.4%-10.0%70.6%
ARDXArdelyx, Inc.LTM Mar 2026$430.6M USD+25.0%+53.7%100.7%
SEPNSepterna, Inc.LTM Sep 2026$169.24M USD+70.9%—175.8%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$152.46M USD+30.0%+8.2%762.3%
IVAInventiva S.A.FY2025€137.37M EUR+28.7%+22.8%3064.2%
BIOABioAge Labs, Inc.LTM Mar 2026$111.96M USD+34.4%+36.6%1085.3%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$36.74M USD+26.3%+34.9%—
Peer median (excluding MAZE) —+28.7%+28.9%145.7%

Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00167.5M0
Cost of Revenue0002.4M
Gross Profit00167.5M(2.4M)
Gross Margin——100.0%—
Research & Development88.19M73.95M83.5M108.45M
Selling, General & Admin22.83M24.61M26.42M34.45M
Operating Expenses111.03M98.55M109.91M140.5M
Depreciation & Amortization3.82M4.09M3.3M2.4M
EBITDA(111.12M)(96.33M)56.7M(128.72M)
EBITDA Margin——33.9%—
Operating Income(111.03M)(98.55M)57.59M(142.9M)
Operating Margin——34.4%—
Interest Income2.03M1.97M4.65M11.78M
Interest Expense0000
Other Income / Expenses(3.91M)(1.86M)(4.18M)11.78M
Income Before Tax(114.94M)(100.42M)53.4M(131.12M)
Pre-Tax Margin——31.9%—
Income Tax Expense001.17M0
Net Income(114.94M)(100.42M)52.23M(131.12M)
Net Margin——31.2%—
EPS (Basic)(2.63)(2.29)0.08(3.05)
EPS (Diluted)(2.63)(2.29)0.08(3.05)
Weighted Avg Shares43.78M43.78M43.8M42.98M
Weighted Avg Shares (Diluted)43.78M43.78M43.8M42.98M

Maze Therapeutics, Inc.

NASDAQ:MAZE

Intrinsic Alpha fair value

Locked

Current Price

$31.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.